drugset / Trial / NCT00003485

Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer

NCT00003485

Phase 2 Terminated 15 enrolled Burzynski Research Institute
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Current therapies for metastatic or unresectable Colon Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of metastatic or unresectable Colon Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with metastatic or unresectable Colon Cancer

Timeline

Start
1996-04-10
Primary completion
2003-05-11
Completion
2003-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject antineoplaston A10 Small molecule Intravenous
Subject antineoplaston AS2-1 Unknown Intravenous

Indications